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Abstract
The herbicide, Galex, containing 25% of metolachlor and 25% of meto-
bromuron dissolved in 46.7% emulsifiable concentrate was widely used 
for the control of grasses and broad-leaf weeds in the 1990s and contin-
ues to be used today. Metobromuron, a substitute urea herbicide, may 
cause methemoglobinemia in humans, but very few studies are available 
about the harmful effects on humans. We report here a case where a 
47-year-old man developed severe methemoglobinemia 10 hours after 
ingestion of 1000 mL of Galex. Acute hypoxic respiratory failure with 
coma occurred suddenly. After ventilator support was instituted, intrave-
nous methylene blue (1%, 2 mg/kg) was administrated immediately. A 
second dose of methylene blue was given because of a persistent high 
level of methemoglobin 2 hours later. The patient was weaned from the 
ventilator on day 4. However, hemolytic anemia, possibly due to the 
administration of methylene blue, occurred and persisted to day 11. This 
resolved gradually only after multiple blood transfusions. Ingestion of a 
large volume of herbicide containing metobromuron, a substituted urea 
herbicide, can induce late-onset methemoglobinemia in humans and, 
while rare, may be fatal if not observed for a sufficient time in the emer-
gency department. Death is possible following the ingestion of this herbi-
cide when adequate diagnoses and treatment are not instituted. Methylene 
blue is useful in reversing methemoglobinemia, but the side effects such 
as hemolytic anemia should be monitored, especially at doses exceeding 
4 mg/kg or in patients with glucose-6-phosphate dehydrogenase (G6PD) 
deficiency. Clinicians should consider the relevant history of G6PD defi-
ciency before using methylene blue to decrease the risk of unnecessary 
hemolytic anemia. Methemoglobinemia in patients with G6PD deficiency 
is best treated with blood transfusions. [Tzu Chi Med J 2009;21(4):
334–338]
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1. Introduction
The herbicide Galex, containing 25% of metobro-
muron and 25% of metolachlor dissolved in 46.7% 
emulsifiable concentrate, was widely used for the con-
trol of grasses and broad-leaf weeds during the 1990s 
and continues to be used today. Metobromuron is a 
substitute urea herbicide, which acts by inhibiting 
photosynthesis [1]. Metolachlor is a herbicide from 
the chloroacetanilide family. Its mode of action is 
elongase inhibition [2]. Galex herbicide consists of 
metobromuron in a solid dispersed form and an or-
ganic phase comprised of metolachlor dissolved in 
an organic hydrophobic solvent, which can increase 
the physical and chemical stability of both chemicals 
[3]. The usage of metolachlor has been decreased be-
cause of the possible risk for mutation of fetuses [2]. 
However, occasional usage still occurs. Metobromuron 
may cause methemoglobinemia in humans, but there 
are very few studies available about the harmful ef-
fects on humans [4,5]. If not adequately diagnosed 
and treated, fatal outcomes are possible. We present 
a case of severe late-onset methemoglobinemia after 
ingestion of a large amount of Galex, which was suc-
cessfully treated using methylene blue.
2. Case report
A 47-year-old man was sent to the emergency depart-
ment (ED) of Tzu Chi General Hospital, 12 hours after 
an intentional ingestion of two bottles (500 mL per 
bottle) of Galex herbicide in April 2006. He had a 
history of suicide attempts by swallowing glyphosate 
1 year prior to this event without sequelae. He was 
initially taken to a local hospital in a stable condition. 
However, a disturbance of his consciousness and cen-
tral cyanosis occurred 10 hours after ingestion, and 
he was unresponsive to oxygen supplement. Endotra-
cheal intubation with mechanical ventilation was in-
stituted. Blood methemoglobin (MetHb) levels were 
58.2%. Intravenous methylene blue (1%, 2 mg/kg) was 
administered immediately. He was transferred to our 
ED in a coma. Bottles with the trade name “Galex” 
herbicide were brought in to the ED by his family.
On arrival to our ED, his vital signs were as follows: 
body temperature was 36.5°C, heart rate was 107 
beats per minute, respiratory rate was 25 breaths 
per minute, and blood pressure was 131/74 mmHg. 
His Glasgow coma scale score was E1VtM1. Cyanotic 
lips and peripheral extremities were noted. Labora-
tory test results showed that white blood cell count 
was 17.2 ˜  103/μL, neutrophils were 92%, lymphocytes 
were 1%, hemoglobin was 13.4 g/dL, platelets were 
209 ˜  103/μL, aspartate aminotransferase level was 
19 IU/L, alanine aminotransferase level was 15 IU/L, 
blood urea nitrogen level was 10 mg/dL, creatinine 
level was 0.9 mg/dL, sodium was 140 mmol/L, and po-
tassium was 4.4 mmol/L. Arterial blood gas data under 
100% oxygen therapy showed that pH was 7.355, 
PaCO2 was 38.4 mmHg, PaO2 was 151.9 mmHg, HCO3
– 
was 22.0 mmol/L, and SaO2 was 99.3%. Follow-up 
blood MetHb levels were 43.5% at 2 hours after the 
first dose of methylene blue. The SaO2 using a CO-
oximeter was 83.7%. A second dose of methylene 
blue (1%, 2 mg/kg) was administered.
The patient was admitted to our medical intensive 
care unit and his consciousness had fully recovered 
1 hour after the second injection of methylene blue. 
Central cyanosis (Fig. 1A), ashen gray skin and “choc-
olate brown” colored blood (Fig. 1B) persisted. Tran-
sient blue-green discoloration of the urine was noted 
Fig. 1 — (A) The patient was intubated with cyanotic lips and ashen gray skin. (B) “Chocolate brown” colored blood 
was noted in the arterial line while methemoglobin was approximately 43.5%.
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later on the same day. Follow-up blood MetHb levels 
were 5.2% on the following morning (10 hours after 
the second methylene blue dose). He was weaned 
from the ventilator on day 4 (Table 1). However, hemo-
lytic anemia was noted on day 4 (hemoglobin was 
6.7 g/dL, haptoglobin was < 10 mg/dL, Heinz bodies). 
His serum total bilirubin level was 28.9 mg/dL and 
direct bilirubin was 21.1 mg/dL on day 6 (Table 1). 
Serum aspartate and alanine aminotransferase lev-
els were 84 IU/L and 88 IU/L, respectively. Abdominal 
sonography showed no signs of biliary tract obstruc-
tion. The patient’s HBs Ag and anti-HCV Ab results 
were negative. Blood transfusion with packed red 
blood cells was required daily until day 11, when a 
follow-up blood MetHb level was 0.1% (Table 1). The 
patient’s hemoglobin level gradually stabilized and 
he was discharged in a stable condition on day 14.
3. Discussion
Methemoglobinemia involves the oxidation of ferrous 
iron to ferric iron, which takes place within the he-
moglobin complex [6,7]. Once MetHb is formed, the 
hemoglobin loses its ability to transport oxygen. 
Methemoglobinemia may occur after exposure to an 
oxidizing chemical, but it may also arise from genetic 
etiologies [8]. Most proven cases of congenital meth-
emoglobinemia have been in persons of European 
descent. Only three Chinese families have been 
unequivocally documented [9,10]. The majority of 
patients with congenital methemoglobinemia are 
asymptomatic despite the intense cyanosis. This is 
a very important differentiating point from acquired 
methemoglobinemia [9]. An intense “chocolate brown” 
colored blood, central cyanosis unresponsive to oxy-
gen supplement, and discrepancy between arterial 
blood gases and pulse oximetry indicates abnormal 
hemoglobin levels [11]. Definite diagnosis can be 
made using a multiple-wavelength CO-oximeter that 
measures oxy-, deoxy-, carboxy-, and MetHb directly 
using spectral absorption.
Metobromuron is a substitute urea herbicide that 
was widely used for the control of grasses and broad-
leaf weeds during the 1990s. Major toxicity of meto-
bromuron has rarely been reported even though it 
is commonly used [4,5]. Methemoglobinemia could 
result from the metabolism of metobromuron to 4-
bromoaniline and 4-bromoacetanilide [5]. In our case, 
the late onset of cyanosis suggests that this mecha-
nism may underlie the patient’s methemoglobinemia. 
It is unlikely that metolachlor induced the methemo-
globinemia as it does not induce methemoglobinemia 
in animals, and there are no case reports of methe-
moglobinemia in humans with metolachlor [4].
Methylene blue is known to be an antidote for met-
hemoglobinemia [11,12]. Methylene blue is reduced to 
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leukomethylene blue by erythrocyte MetHb reductase, 
subsequently facilitating reduction of MetHb to oxy-
hemoglobin [13]. It is generally reserved for patients 
with symptomatic MetHb levels over 20%, or over 
10% in those individuals with preexisting conditions 
that interfere with tissue oxygenation (e.g. anemia 
and coronary insufficiency) [14]. However, hemolytic 
anemia and even methemoglobinemia have been re-
ported after the administration of methylene blue 
[15,16]. It has been recommended that methylene 
blue be intravenously administered in 1–2 mg/kg 
doses for 5–10 minutes, with the total dose not ex-
ceeding 15 mg/kg [11]. Because the maximum effect 
of methylene blue is at 30 minutes, it may be neces-
sary to repeat the dose of 1 mg/kg within 1 hour for 
MetHb levels over 60%, or when the patient’s condi-
tion does not improve [14]. Our patient received a 
second dose of intravenous methylene blue (2 mg/
kg) because of the persistent high level of MetHb 
(43.5%) at 2 hours after the first dose. At doses ex-
ceeding 4 mg/kg, blue-green discoloration of the 
urine and feces due to leukomethylene blue and 
hemolytic anemia may occur, as noted in our patient 
[14]. Hemolytic anemia may be delayed for several 
days and delay can even be up to 10 days after ad-
ministration [14]. Monitoring the blood counts is 
necessary. Methylene blue should be used carefully 
in young patients with glucose-6-phosphate dehydro-
genase (G6PD) deficiency due to low endogenous 
concentrations of NADPH, which is necessary for leu-
komethylene blue production. These patients can 
develop hemolytic anemia without any reduction in 
methemoglobin levels [17]. It has been suggested 
that low doses of methylene blue (< 1 mg/kg) may be 
beneficial in these individuals [17]. Methylene blue 
doses greater than 4 mg/kg can exhibit oxidizing 
effects in these patients, resulting in hemolysis. 
Methemoglobinemia in patients with G6PD deficiency 
is best treated with blood transfusions [17]. Despite 
our patient never having been tested for G6PD defi-
ciency, we believe that he did not suffer from this con-
dition due to the effective reduction of MetHb levels 
using methylene blue.
It is quite plausible that the hemolytic anemia in 
our patient was the result of the methylene blue. 
Hemolysis developed prior to the transfusion, exclud-
ing the transfusion reaction as the cause of the initial 
hemolysis. However, prolonged methemoglobinemia 
and ongoing oxidative stress may itself produce hemo-
lysis, and it is possible that the hemolysis in our case 
was the result of exposure to metobromuron or, pos-
sibly, to both agents [4,8].
There have only been two similar cases reported 
in the English literature [4,5]. The first case was a 
22-year-old woman who was 36 weeks pregnant and 
developed central cyanosis 15 hours after inges-
tion of 500 mL of Galex herbicide [4]. She received 
1.5 mg/kg methylene blue intravenously with reversal 
of her central cyanosis 40 minutes after admission. 
The MetHb, which was not measured at admission, 
was still pos itive (5%) 50 hours post ingestion. The 
second case, a 36-year-old male alcoholic, appeared 
with diffuse cyanosis 17 hours after ingestion of beer 
(nearly 3 L) and 250 mL of a commercial herbicide 
“Patoran” containing 50% metobromuron and 7% 
propylene glycol in water [5]. An 80% MetHb level 
was detected on admission. He received three doses 
of intravenous 2 mg/kg methylene blue for relapsing 
MetHb. Both patients fully recovered, but the second 
patient experienced transient hemolysis similar to 
our case report after the dosage had accumulated 
to 4 mg/kg.
In conclusion, ingestion of a large volume of her-
bicide containing metobromuron can induce methe-
moglobinemia. The onset of methemoglobinemia may 
be delayed for hours. Prolonged close observation in 
hospital is necessary. There is the potential for death 
following ingestion of herbicides containing metobro-
muron when adequate diagnosis and treatment are 
not instituted. Methylene blue is useful in reversing 
methemoglobinemia, but the side effects, such as he-
molytic anemia, should be monitored, especially at 
doses exceeding 4 mg/kg or in patients with G6PD de-
ficiency. Clinicians should attain relevant medical his-
tories of G6PD deficiency before the use of methylene 
blue to decrease unnecessary hemolytic anemia. 
Methemoglobinemia in patients with G6PD deficiency 
is best treated with a blood transfusion.
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